PT-141 (Bremelanotide)
Melanocortin agonist FDA-approved (Vyleesi) for HSDD; libido enhancement.
Scientific Overview
Bremelanotide (Vyleesi) is FDA-approved for premenopausal HSDD. Acts on MC4R in the hypothalamus.
Key Research Benefits
- ✓Increases libido
- ✓Acts on CNS, not vascular
- ✓Works in both sexes
Potential Side Effects
Research Protocols
Common DosagesOn-Demand
“Max 1 dose/24h, 8 doses/month”
Dose Calculator
🧮 Peptide Reconstitution Calculator
Total amount of peptide in the vial.
Volume of water used to mix.
Draw to this mark
or 0.40 mL on a U-100 syringe
Explore PT-141 (Bremelanotide)
Where to source
Vendors with public COAs that stock this category. Affiliate links are disclosed.
- Limitless Life NootropicsFL-based research-peptide supplier with Janoshik third-party COAs and a public affiliate program at ~20%.COA: JanoshikAffiliate disclosed
- SwissChems60+ peptide catalog with Janoshik COAs; weekly affiliate payouts.COA: JanoshikAffiliate disclosed
- Amino ClubEU/US-facing vendor with a 20% first-order / 10% recurring affiliate model.COA: Third-partyAffiliate disclosed
PT-141 (Bremelanotide) by goal
Read PT-141 (Bremelanotide)'s profile filtered through specific research goals.
Molecular Profile
Quick Reference
- Status
- Research Compound
- Category
- Cosmetic
- Common Dosage
- 1.0–1.75 mg
- ≥45 min before activity
Strictly for research purposes. Not for human consumption.
Related tools
Medical Disclaimer
Information provided on DoseVault is for educational and research purposes only. This website does not advocate for the human use of peptides. Peptides are currently sold as research chemicals and are not FDA-approved for human consumption. Always consult a licensed medical professional before considering any protocol.